Published in Am J Hematol on October 01, 2010
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica (2012) 1.10
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood (2012) 1.08
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica (2013) 0.94
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood (2012) 0.86
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood (2017) 0.78
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia (2016) 0.75
Cardioverter-defibrillator implantation in myeloma-associated cardiac amyloidosis. Exp Clin Cardiol (2013) 0.75
Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis. Am J Hematol (2015) 0.75
Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart (2017) 0.75
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood (2006) 2.97
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2006) 1.94
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet (2003) 1.64
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid (2003) 1.47
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica (2012) 1.10
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Multiple myeloma. Blood (2008) 5.88
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Genetic progression and the waiting time to cancer. PLoS Comput Biol (2007) 3.57
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood (2012) 3.44
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging (2010) 3.03
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc (2007) 2.91
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood (2007) 2.87
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol (2011) 2.82
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood (2003) 2.68
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem (2005) 2.64
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol (2002) 2.63
Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc (2004) 2.62